Table S4. Univariate and multivariate analysis of predictive factor for OS and survival after the first progression post-SABR for the whole patients.
| Characteristics | OS | Survival after the first progression post-SABR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Age (continuous) | 1.00 (0.95–1.05) | 0.89 | – | – | 1.02 (0.97–1.08) | 0.34 | – | – | |||
| Age | – | – | |||||||||
| <70 years | 0.86 (0.36–2.05) | 0.74 | – | – | 1.40 (0.47–2.21) | 0.54 | – | ||||
| ≥70 years | – | – | – | – | – | – | – | ||||
| Gender | |||||||||||
| Male | 0.78 (0.31–1.97) | 0.60 | – | – | 0.33 (0.10–1.10) | 0.07 | 0.15 (0.02–0.88) | 0.03 | |||
| Female | – | – | – | – | – | – | – | ||||
| FEV1 (continuous) | 0.99 (0.97–1.01) | 0.46 | – | – | 0.99 (0.97–1.02) | 0.85 | – | – | |||
| FEV1 | – | ||||||||||
| <40% of predicted | 0.47 (0.17–1.26) | 0.13 | – | – | 0.38 (0.07–1.93) | 0.42 | – | ||||
| ≥40% of predicted | – | – | – | – | – | – | – | ||||
| DLCO (continuous) | 0.98 (0.95–1.00) | 0.15 | – | – | 0.98 (0.95–1.01) | 0.31 | – | – | |||
| DLCO | – | ||||||||||
| <40% of predicted | 0.98 (0.95–1.00) | 0.16 | – | – | 0.88 (0.16–4.85) | 0.88 | – | ||||
| ≥40% of predicted | – | – | – | – | – | – | – | ||||
| Supplemental O2 | – | ||||||||||
| Needed | 3.49 (1.52–10.25) | 0.005 | 3.40 (1.25–9.22) | 0.01 | 1.68 (0.46–6.18) | 0.43 | – | ||||
| Not-needed | – | – | – | – | – | – | – | ||||
| KPS | 0.08 | ||||||||||
| ≤70% | 0.42 (0.17–1.01) | 0.05 | 0.51 (0.20–1.32) | 0.16 | 0.33 (0.09–1.22) | 0.09 | 0.16 (0.02–1.27) | ||||
| >70% | – | – | – | – | – | – | – | ||||
| CVD | – | ||||||||||
| Yes | 1.27 (0.53–3.05) | 0.58 | – | – | 0.76 (0.26–2.19) | 0.62 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| COPD | – | ||||||||||
| Yes | 1.43 (0.59–3.48) | 0.60 | – | – | 1.97 (0.66– 5.91) | 0.22 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Comorbidity | – | ||||||||||
| One or more | 1.46 (0.42–5.06) | 0.54 | – | – | 2.18 (0.47–9.95) | 0.31 | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Pre-chemotherapy | – | ||||||||||
| Yes | 0.79 (0.33–1.89) | 0.60 | – | – | 0.70 (0.24–2.05) | 0.51 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Post-chemotherapy | 0.36 | ||||||||||
| Yes | 0.85 (0.35–2.07) | 0.73 | – | – | 0.37 (0.11–1.17) | 0.09 | 0.47 (0.09–2.39) | ||||
| No | – | – | – | – | – | – | – | ||||
| Chemotherapy | – | ||||||||||
| One or both pre or post | 0.80 (0.32–1.98) | 0.63 | – | – | 0.48 (0.14–1.67) | 0.25 | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Pre-lung irradiation | – | ||||||||||
| Yes | 0.86 (0.20–3.71) | 0.84 | – | – | 0.96 (0.21–4.37) | 0.96 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Pre-lung surgery | 0.71 | ||||||||||
| Yes | 0.78 (0.30–2.03) | 0.62 | – | – | 0.24 (0.05–1.15) | 0.07 | 0.63 (0.05–7.71) | ||||
| No | – | – | – | – | – | – | – | ||||
| Pre-lung treatment | – | ||||||||||
| One or both | 0.71 (0.28–1.78) | 0.47 | – | – | 0.33 (0.08–1.29) | 0.11 | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Post-lung irradiation | – | ||||||||||
| Yes | 0.68 (0.16–2.95) | 0.61 | – | – | 0.52 (0.06–4.13) | 0.53 | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Post-lung surgery | – | ||||||||||
| Yes | 1.06 (0.14–0.7.98) | 0.95 | – | – | – | – | – | ||||
| No | – | – | – | – | – | – | – | ||||
| Post- lung treatment | – | ||||||||||
| One or both | 0.72 (0.16–3.12) | 0.66 | – | – | – | – | – | ||||
| None | – | – | – | – | – | – | – | ||||
| Lung local treatment | 0.84 | ||||||||||
| One or both pre or post | 0.64 (0.26–1.53) | 0.32 | – | – | 0.22 (0.05–0.86) | 0.03 | 1.30 (0.09–18.97) | ||||
| None | – | – | – | – | – | – | – | ||||
| Number of lesions | – | ||||||||||
| One lesion | 1.83 (0.77–4.36) | 0.17 | – | – | 0.47 (0.14–1.57) | 0.22 | – | ||||
| More than one | – | – | – | – | – | – | – | ||||
| Type of cancer | 0.10 | ||||||||||
| Primary | 0.45 (0.15–1.36) | 0.15 | – | – | 0.11 (0.01–0.88) | 0.03 | 0.17 (0.02–1.44) | ||||
| Metastatic | – | – | – | – | – | – | – | ||||
| After progression | – | ||||||||||
| Salvage treatments | 1.28 (0.45–3.67) | 0.63 | – | – | 0..40 (0.13–1.22) | 0.11 | – | ||||
| No treatments | – | – | – | – | – | – | – | ||||
OS, overall survival; SABR, stereotactic ablative radiotherapy; HR, hazard ratio; FEV1, forced expiration at the first second; DLCO, diffusing capacity of the Lung for carbon monoxide; KPS, Karnofsky`s performance status; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease.